0.18
-0.0036(-2.02%)
Currency In USD
| Previous Close | 0.18 |
| Open | 0.18 |
| Day High | 0.18 |
| Day Low | 0.17 |
| 52-Week High | 3.43 |
| 52-Week Low | 0.16 |
| Volume | 211,258 |
| Average Volume | 4.88M |
| Market Cap | 3.76M |
| PE | -0.11 |
| EPS | -1.6 |
| Moving Average 50 Days | 0.25 |
| Moving Average 200 Days | 0.5 |
| Change | -0 |
If you invested $1000 in Oragenics, Inc. (OGEN) 10 years ago, it would be worth $0.34 as of April 19, 2025 at a share price of $0.175. Whereas If you bought $1000 worth of Oragenics, Inc. (OGEN) shares 5 years ago, it would be worth $7.55 as of April 19, 2025 at a share price of $0.175.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Oragenics, Inc. Announces Health and Disability Ethics Committee Submission for Phase IIa Concussion Trial
GlobeNewswire Inc.
Apr 09, 2025 12:58 PM GMT
SARASOTA, Fla., April 09, 2025 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a biotechnology company focused on developing novel intranasal therapies for brain-related conditions, today announced that it has submitted a clinical trial
Oragenics, Inc. Participates in the 3rd Nasal Formulation & Delivery Summit
GlobeNewswire Inc.
Apr 07, 2025 8:30 PM GMT
SARASOTA, Fla., April 07, 2025 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a biotechnology company focused on developing novel intranasal therapies for brain-related disorders, today announced that Chief Medical Officer Dr. James Kel
Oragenics, Inc. Provides Q1 2025 Shareholder Update on Strategic and Financial Progress
GlobeNewswire Inc.
Mar 27, 2025 12:30 PM GMT
ONP-002 Advances Toward Phase IIa Concussion Trial with Strengthened Financial Foundation and Industry MomentumSARASOTA, Fla., March 27, 2025 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a biotechnology company focused on developing n
Data not available